For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after ...
Morning Overview on MSN
The same weight-loss drugs were linked to lower depression and anxiety
The same GLP-1 medications reshaping weight loss have been linked to lower rates of depression and anxiety, adding to a ...
Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments. Just as ...
Add Yahoo as a preferred source to see more of our stories on Google. Early evidence that a drug used for rheumatoid arthritis may reduce depression symptoms, fatigue, anxiety and increase overall ...
-- Reposted from the online magazine, "The Trauma & Mental Health Report" The pharmaceutical industry grosses over $300 billion a year in psychotropic medication sales. Included in this figure are ...
An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...
This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Janet Babin: Hey, Future of Everything listeners, it's Janet Babin. Earlier this ...
Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results